A modern approach to the treatment of mitochondrial disease
- 14 October 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in Current Treatment Options in Neurology
- Vol. 11 (6), 414-430
- https://doi.org/10.1007/s11940-009-0046-0
Abstract
Opinion statement The treatment of mitochondrial disease varies considerably. Most experts use a combination of vitamins, optimize patients’ nutrition and general health, and prevent worsening of symptoms during times of illness and physiologic stress. We agree with this approach, and we agree that therapies using vitamins and cofactors have value, though there is debate about the choice of these agents and the doses prescribed. Despite the paucity of high-quality scientific evidence, these therapies are relatively harmless, may alleviate select clinical symptoms, and theoretically may offer a means of staving off disease progression. Like many other mitochondrial medicine physicians, we have observed significant (and at times life-altering) clinical responses to such pharmacologic interventions. However, it is not yet proven that these therapies truly alter the course of the disease, and some experts may choose not to use these medications at all. At present, the evidence of their effectiveness does not rise to the level required for universal use. Based on our clinical experience and judgment, however, we agree that a therapeutic trial of coenzyme Q10, along with other antioxidants, should be attempted. Although individual specialists differ as to the exact drug cocktail, a common approach involves combinations of antioxidants that may have a synergistic effect. Because almost all relevant therapies are classified as medical foods or over-the-counter supplements, most physicians also attempt to balance the apparent clinical benefit of mitochondrial cocktails with the cost burden that these supplements pose for the family.Keywords
This publication has 67 references indexed in Scilit:
- RETRACTED: Activation of the PPAR/PGC-1α Pathway Prevents a Bioenergetic Deficit and Effectively Improves a Mitochondrial Myopathy PhenotypeCell Metabolism, 2008
- ADCK3, an Ancestral Kinase, Is Mutated in a Form of Recessive Ataxia Associated with Coenzyme Q10 DeficiencyAmerican Journal of Human Genetics, 2008
- Large-scale chemical dissection of mitochondrial functionNature Biotechnology, 2008
- The in-depth evaluation of suspected mitochondrial diseaseMolecular Genetics and Metabolism, 2008
- Prenyldiphosphate synthase, subunit 1 (PDSS1) and OH-benzoate polyprenyltransferase (COQ2) mutations in ubiquinone deficiency and oxidative phosphorylation disordersJCI Insight, 2007
- Leigh Syndrome with Nephropathy and CoQ10 Deficiency Due to decaprenyl diphosphate synthase subunit 2 (PDSS2) MutationsAmerican Journal of Human Genetics, 2006
- Effects of riboflavin in children with complex II deficiencyBrain & Development, 2006
- Toxicology of oral antidiabetic medicationsAmerican Journal of Health-System Pharmacy, 2006
- Anti-HIV drugs and the mitochondriaBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2006
- Horseback riding in children with cerebral palsy: effect on gross motor functionDevelopmental Medicine and Child Neurology, 2002